Vanguard Group
ASBP

Vanguard Group’s Aspire Biopharma ASBP Stock Holding History

Vanguard Group’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$56.6K Hold
357
– – ﹤0.01% 4229
2025
Q3 		$88.3K Buy
+357
New +$179K ﹤0.01% 4238

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
OAS
Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
RA
Resolute Advisors San Francisco, California $242M AUM 52.95% 1-Year Est. Return
TSW
Three Seasons Wealth Salt Lake City, Utah $262M AUM 45.03% 1-Year Est. Return

Vanguard Group's ASBP Position: Q4 2025 in Review

Vanguard Group held its Aspire Biopharma (ASBP) position steady in Q4 2025 at 357 shares worth $56.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4229.

Vanguard Group first reported a position in ASBP in Q3 2025 and has held it in 2 quarters since. The position peaked at $88.3K in Q3 2025. 28 funds tracked by Wall St. Rank hold ASBP as of Q4 2025.

  • Vanguard Group held 357 shares of Aspire Biopharma worth $56.6K as of Q4 2025.
  • Vanguard Group left its Aspire Biopharma share count unchanged in Q4 2025.
  • Aspire Biopharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4229 holding.
  • Vanguard Group first reported a position in Aspire Biopharma in Q3 2025 and has held it in 2 quarters since.
  • Vanguard Group's Aspire Biopharma position peaked at $88.3K in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Aspire Biopharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.